[The Bell] CG MedTech Partners on CDMO for Allogeneic Dermis Product
Predicted impact: Low
CDMO collaboration on a dermis product; size and terms unknown, likely small.
056090 · KOSDAQ · ₩056090 · 시지메드텍
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−75.4% from the high
₩4,220Today: ₩4,325 – ₩4,510₩17,775
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
CG MedTech (시지메드텍, KRX: 056090) is listed on KOSDAQ, in the Medical & precision devices sector. The company operates two business segments: medical devices and electrical energy. Its shares closed at ₩4,370 on Oct 28, 2026, down 1.69% on the day, giving it a market value of ₩90B.
The company operates two business segments: medical devices and electrical energy. Its medical device segment makes orthopedic products such as spinal fixation devices, fracture treatment devices, minimally invasive devices, bioabsorbable metal implants, dental implants and spinal bone graft materials. Its electrical energy segment supplies electricity meters, heat meters, electric vehicle chargers and testing equipment, and takes part in government-led smart metering and renewable energy projects.
Written by AI from the company's latest annual report.
Predicted impact: Low
CDMO collaboration on a dermis product; size and terms unknown, likely small.
Predicted impact: Low
Titles in Korean until English translations are added.
Also known as: CG MedTech / 시지메드텍 / 056090 / KRX:056090
Source: KRX statistical information